Temsirolimus

Search with Google Search with Bing

Information
Drug Name
Temsirolimus
Description
Entry(CIViC)
11
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
renal carcinoma VHL LOSS
( ENST00000256474.3 ) VHL LOSS
( ENST00000256474.3 ) 		D Predictive Supports Sensitivity/Response Somatic 3 16341243 Detail
endometrial cancer PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		D Predictive Supports Sensitivity/Response Somatic 3 23674493 Detail
thyroid cancer PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19706758 Detail
thyroid cancer PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19706758 Detail
thyroid cancer PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) 		D Predictive Supports Sensitivity/Response N/A 2 19706758 Detail
sarcoma BRAF KIAA1549-BRAF C Predictive Supports Sensitivity/Response Somatic 2 24422672 Detail
prostate cancer PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		D Predictive Supports Sensitivity/Response Somatic 4 11504908 Detail
breast cancer NF2 K159FS*16
( ENST00000338641.10 ) NF2 K159FS*16
( ENST00000338641.10 ) 		C Predictive Supports Sensitivity/Response Somatic 3 25878190 Detail
endometrial cancer PIK3CA MUTATION PIK3CA MUTATION B Predictive Does Not Support Sensitivity/Response Somatic 3 24166148 Detail
endometrial cancer PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		B Predictive Does Not Support Resistance Somatic 3 24166148 Detail
endometrial cancer KRAS MUTATION KRAS MUTATION B Predictive Does Not Support Sensitivity/Response Somatic 2 24166148 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Preclinical studies linking the efficacy of mTOR i... VHL VHL LOSS
( ENST00000256474.3 ) VHL LOSS
( ENST00000256474.3 ) 		Sensitivity true CIViC Evidence detail
A panel of 24 endometroid endometrial cancer (EEC)... PTEN PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		Sensitivity true CIViC Evidence detail
Preclinical study in thyroid cancer cell lines. 6 ... PIK3CA PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.His1047Arg (p.H1047R)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
Preclinical study in thyroid cancer cell lines. 6 ... PIK3CA PIK3CA p.Glu542Lys (p.E542K)
( ENST00000643187.1, ENST00000263967.4 ) PIK3CA p.Glu542Lys (p.E542K)
( ENST00000263967.4, ENST00000643187.1 ) 		Sensitivity true CIViC Evidence detail
Preclinical study in thyroid cancer cell lines. 6 ... PTEN PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) PTEN p.Arg130Ter (p.R130*)
( ENST00000371953.8, ENST00000472832.3, ENST00000688308.1, ENST00000700021.1, ENST00000700029.2, ENST00000713839.1 ) 		Sensitivity true CIViC Evidence detail
A patient with a malignant spindle cell tumor of t... BRAF BRAF KIAA1549-BRAF Sensitivity true CIViC Evidence detail
In prostate cancer xenographs, PTEN null tumors ha... PTEN PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		Sensitivity true CIViC Evidence detail
23 patients were treated with temsirolimus contain... NF2 NF2 K159FS*16
( ENST00000338641.10 ) NF2 K159FS*16
( ENST00000338641.10 ) 		Sensitivity true CIViC Evidence detail
94 endometrial cancer samples of women who had bee... PIK3CA PIK3CA MUTATION PIK3CA MUTATION Sensitivity false CIViC Evidence detail
94 endometrial cancer samples of women who had bee... PTEN PTEN DELETION
( ENST00000371953.8 ) PTEN DELETION
( ENST00000371953.8 ) 		Resitance or Non-Reponse false CIViC Evidence detail
94 endometrial cancer samples of women who had bee... KRAS KRAS MUTATION KRAS MUTATION Sensitivity false CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02420613 Active, not recruiting Phase 1 Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma October 5, 2015 October 31, 2024
NCT00600496 Active, not recruiting Phase 1 A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) December 14, 2007 December 31, 2024
NCT01529593 Active, not recruiting Phase 1 Temsirolimus in Combination With Metformin in Patients With Advanced Cancers March 26, 2012 June 1, 2024
NCT02567435 Active, not recruiting Phase 3 Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma June 1, 2016 October 1, 2024
NCT02389309 Active, not recruiting Phase 1 Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors October 5, 2015 October 31, 2024
NCT01396408 Active, not recruiting Phase 2 A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours February 9, 2012 December 31, 2024
NCT01375829 Active, not recruiting Phase 1 Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery June 27, 2011 March 7, 2025
NCT01946529 Active, not recruiting Phase 2 Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors December 27, 2013 July 2026
NCT01187199 Active, not recruiting Phase 1 Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer August 19, 2010 April 30, 2026
NCT01552434 Active, not recruiting Phase 1 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease March 16, 2012 March 31, 2026
NCT01087554 Active, not recruiting Phase 1 Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer March 2010 August 18, 2026
NCT00980460 Active, not recruiting Phase 3 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer September 14, 2009 March 5, 2025
NCT00977574 Active, not recruiting Phase 2 Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer September 14, 2009 March 6, 2025
NCT00084916 Completed Phase 2 CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase April 2004
NCT00087074 Completed Phase 2 CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor June 2004
NCT00093782 Completed Phase 2 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma December 2003 April 2011
NCT00098501 Completed Phase 1 CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors October 2004
NCT00109967 Completed Phase 2 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma May 2005 March 2012
NCT00112476 Completed Phase 1 Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors March 2005
NCT00112736 Completed Phase 1/Phase 2 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma April 2005 April 2014
NCT00195299 Completed Study Evaluating Temsirolimus in Advanced Stage Squamous Cell Carcinoma of the Head & Neck April 2005 February 2007
NCT00235794 Completed N/A An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients January 2004 September 2007
NCT00255658 Completed Phase 1 Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors September 2005 April 2007
NCT00275093 Completed Phase 1 Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function December 2005
NCT00281957 Completed Phase 2 Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery August 2007 January 2011
NCT00290472 Completed Phase 2 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia March 2004 April 2010
NCT00316849 Completed Phase 1 Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme May 2006
NCT00329719 Completed Phase 1/Phase 2 Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma March 24, 2006 February 2, 2013
NCT00335764 Completed Phase 1/Phase 2 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma April 2006 September 2012
NCT00349206 Completed Phase 1 Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma April 2006 February 2012
NCT00376688 Completed Phase 2 Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer July 11, 2006 December 16, 2019
NCT00378703 Completed Phase 2 Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer September 14, 2007 March 21, 2017
NCT00397982 Completed Phase 2 Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma January 2008 July 2013
NCT00398515 Completed Phase 1 Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma March 2007
NCT00408655 Completed Phase 1 Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors February 2007
NCT00429793 Completed Phase 2 Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer February 2007 January 2012
NCT00593060 Completed Phase 1 Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer November 1, 2007 November 2010
NCT00610493 Completed Phase 1 Bevacizumab and Temsirolimus in Patients With Advanced Malignancy January 25, 2008 November 28, 2017
NCT00619268 Completed Phase 2 Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma February 2008 February 2012
NCT00631371 Completed Phase 3 Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects April 2008 April 2015
NCT00659568 Completed Phase 1 Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma March 2008 August 2010
NCT00678769 Completed Phase 1 Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer May 2008 October 2015
NCT00693433 Completed Phase 1 Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma December 2008
NCT00699491 Completed Phase 1/Phase 2 Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer October 31, 2008 February 14, 2018
NCT00700258 Completed Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] February 13, 2008 December 28, 2021
NCT00703170 Completed Phase 1 Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies March 2008 July 2011
NCT00703625 Completed Phase 1 Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies March 8, 2008 June 1, 2011
NCT00723255 Completed Phase 2 Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer September 2008 January 25, 2016
NCT00729586 Completed Phase 2 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer September 2008 February 2017
NCT00761644 Completed Phase 1 Doxil, Bevacizumab and Temsirolimus Trial August 21, 2008 March 28, 2019
NCT00770263 Completed Phase 1 Erlotinib and Temsirolimus for Solid Tumors May 2009 September 2014
NCT00775593 Completed Phase 2 Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia December 2008 October 23, 2013
NCT00782275 Completed Phase 2 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma April 2009 May 2015
NCT00784914 Completed Phase 1 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors June 2008 November 2010
NCT00787969 Completed Phase 1 Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma April 2009 June 15, 2017
NCT00796796 Completed Phase 1 Temsirolimus and Radiation for Non-Small Cell Lung Cancer March 2009 July 2011
NCT00800917 Completed Phase 2 A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme November 2008 February 2010
NCT00827684 Completed Phase 2 Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations March 2009 June 2011
NCT00838539 Completed Phase 1 Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors April 2009 December 2013
NCT00880282 Completed Phase 1 Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment April 2009
NCT00909831 Completed Phase 1 Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment October 2008 November 2013
NCT01460979 Completed Phase 2 Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma October 2011 November 2015
NCT00012142 Completed Phase 2 CCI-779 in Treating Patients With Prostate Cancer September 2000 March 2004
NCT00016328 Completed Phase 2 CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme May 2001
NCT00022464 Completed Phase 2 CCI-779 in Treating Patients With Metastatic Melanoma June 2001 September 2005
NCT00022724 Completed Phase 1/Phase 2 CCI-779 in Treating Patients With Malignant Glioma August 27, 2001 December 15, 2007
NCT00028028 Completed Phase 2 CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer February 2002
NCT00033267 Completed Phase 2 CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma April 2002 February 2008
NCT00045370 Completed Phase 1 Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer April 2002 November 2003
NCT00071968 Completed Phase 2 Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse August 2003
NCT00072176 Completed Phase 2 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer May 2004 August 2009
NCT00075647 Completed Phase 2 CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer December 2003
NCT00079235 Completed Phase 2 CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer February 2004
NCT00079456 Completed Phase 2 Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma February 2004
NCT01076543 Completed Phase 1/Phase 2 Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma April 15, 2010 September 30, 2018
NCT01083368 Completed Phase 1/Phase 2 Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy January 2009 October 2014
NCT01090466 Completed Phase 1/Phase 2 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium February 2008 March 16, 2016
NCT01111825 Completed Phase 1/Phase 2 Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer April 2010 July 2016
NCT01122615 Completed Phase 1 Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) May 2010 July 2014
NCT01141244 Completed Phase 1 Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors June 2010
NCT01155258 Completed Phase 1 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors June 2010 May 2014
NCT01172769 Completed Phase 2 Efficacy Study of Temsirolimus to Treat Head and Neck Cancer June 2010 March 2012
NCT01180049 Completed Phase 4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma March 2011 June 2018
NCT01183663 Completed Phase 1 Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) August 2010 May 2016
NCT01196429 Completed Phase 2 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer August 2010 January 2015
NCT01198184 Completed Phase 1 Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors August 2010 October 2013
NCT01206036 Completed Phase 1/Phase 2 CESAR Study in Prostate Cancer With Temsirolimus Added to Standard Docetaxel Therapy (CEPTAS) July 2010 October 2015
NCT01206140 Completed Phase 2 Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery October 2010 April 2015
NCT01210482 Completed Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) August 2010 March 2018
NCT01222715 Completed Phase 2 Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma October 2010 June 2015
NCT01256385 Completed Phase 2 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy November 2010 December 2013
NCT01281917 Completed Phase 2 Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma February 2011 June 2014
NCT01381692 Completed Phase 1/Phase 2 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma July 20, 2011 September 1, 2021
NCT01392183 Completed Phase 2 Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC) October 24, 2012 September 8, 2019
NCT01403415 Completed Phase 1 Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma September 2011
NCT01417065 Completed Early Phase 1 Temsirolimus In Phase 0 August 2010
NCT00003712 Completed Phase 1 CCI-779 in Treating Patients With Advanced Solid Tumors January 2001 June 2002
NCT01517243 Completed Phase 2 Phase II Study of Alternating Sunitinib and Temsirolimus September 22, 2010 August 20, 2018
NCT01529138 Completed Phase 1 Study of Axitinib and Temsirolimus in Solid Tumors October 2011 March 2014
NCT01535989 Completed Phase 1 Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma December 2011 June 2016
NCT01548482 Completed Phase 1 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery March 2012 January 2014
NCT01596140 Completed Phase 1 Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer December 18, 2012 June 1, 2020
NCT01611116 Completed Phase 2 Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia May 2012 April 26, 2017
NCT01614197 Completed Phase 1 A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma July 3, 2015 September 4, 2020
NCT01614795 Completed Phase 2 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma June 18, 2012 April 1, 2014
NCT01625156 Completed Phase 1 Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery May 2012 October 2015
NCT01646021 Completed Phase 3 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy December 10, 2012 December 15, 2016
NCT01687673 Completed Phase 2 Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma October 5, 2012 January 9, 2020
NCT01712828 Completed Phase 1 Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males October 1, 2012 January 1, 2013
NCT01767194 Completed Phase 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma February 12, 2013 September 30, 2022
NCT01827267 Completed Phase 2 Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer July 1, 2013 October 6, 2017
NCT01827943 Completed Phase 2 Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer June 2009 December 2016
NCT01902160 Completed Phase 1 Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma September 2013
NCT02093598 Completed Phase 2 POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus May 2012 March 2014
NCT02238496 Completed Phase 1 Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas December 8, 2014 February 14, 2021
NCT02343718 Completed Phase 1 Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours June 24, 2015 January 16, 2019
NCT03158389 Completed Phase 1/Phase 2 NCT Neuro Master Match - N²M² (NOA-20) May 7, 2018 February 22, 2023
NCT00979966 Completed Phase 2 Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib July 2009
NCT00998036 Completed Phase 1 Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors September 2009 October 2012
NCT01010126 Completed Phase 2 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer September 8, 2009 March 13, 2017
NCT01016015 Completed Phase 2 Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma November 2009 July 2014
NCT01019434 Completed Phase 2 Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma October 2009 March 2014
NCT01026623 Completed Phase 1/Phase 2 Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer October 2009 February 2013
NCT01026792 Completed Phase 2 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery December 2009 November 2012
NCT01051557 Completed Phase 1/Phase 2 Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma January 27, 2010 September 30, 2020
NCT01065662 Completed Phase 1 AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies February 2010 March 2021
NCT04433572 Not yet recruiting Phase 3 Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee December 1, 2020 December 1, 2025
NCT04199026 Not yet recruiting Early Phase 1 Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma January 31, 2025 December 31, 2025
NCT03297606 Recruiting Phase 2 Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) March 23, 2018 January 31, 2027
NCT03942601 Recruiting Phase 2 Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization October 1, 2019 August 15, 2024
NCT03571438 Recruiting N/A Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors October 16, 2017 September 30, 2024
NCT02446431 Recruiting Early Phase 1 Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence July 2014 July 2029
NCT03203525 Recruiting Phase 1 Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer June 23, 2020 December 31, 2026
NCT02693535 Recruiting Phase 2 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer March 14, 2016 December 31, 2025
NCT05773326 Recruiting Early Phase 1 Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG May 15, 2023 April 30, 2026
NCT00593008 Terminated Phase 1 Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer October 2007 October 2009
NCT01079767 Terminated Phase 2 Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis January 2010
NCT00921310 Terminated Phase 1/Phase 2 Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer September 2009 April 2016
NCT01111448 Terminated Phase 2 Temsirolimus in Myelodysplastic Syndrome (MDS) April 2010 June 2014
NCT00808899 Terminated Phase 2 Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma December 2008 July 2009
NCT01264341 Terminated Phase 2 Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma December 2010 July 2015
NCT00926107 Terminated Phase 2 Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse June 2009 October 2011
NCT01009203 Terminated Phase 2 Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma December 2009 December 2012
NCT00877773 Terminated Phase 1/Phase 2 Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients April 2009 June 2014
NCT01015664 Terminated Phase 1/Phase 2 Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck February 2010 December 2012
NCT01378377 Terminated Phase 1 Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus May 27, 2011 February 23, 2012
NCT01020305 Terminated Phase 1/Phase 2 Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer October 2009 April 2012
NCT00838955 Terminated Phase 2 Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma January 2009 October 2017
NCT01061606 Terminated Phase 2 Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus January 2010 October 2012
NCT01166126 Terminated Phase 2 Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV October 2010 June 2012
NCT01174199 Terminated Phase 1 Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer February 2012 August 2016
NCT00512668 Terminated Phase 1 Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer September 2007
NCT00101088 Terminated Phase 1 Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia April 2005
NCT00887640 Terminated Phase 2 Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer July 2009 August 2012
NCT02423954 Terminated Phase 1/Phase 2 Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) April 2015 November 1, 2017
NCT01204450 Terminated Phase 1 Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma November 2009 March 2013
NCT02560012 Terminated Phase 2 Personalized Targeted Inhibitors Treatment in Renal Cell Cancer January 4, 2016 July 27, 2017
NCT00086840 Terminated Phase 2 CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia May 2004
NCT01567930 Unknown status Phase 2 Temsirolimus as Second-line Therapy in HCC February 2010 March 2013
NCT01246817 Unknown status Phase 2 Temsirolimus-RCC-imaging August 2009
NCT02215720 Unknown status Phase 1 Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors April 2011 October 2016
NCT02908035 Unknown status Phase 2 Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO) March 3, 2017 September 2021
NCT00942747 Unknown status Phase 2 Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma July 2009 June 2014
NCT01182883 Withdrawn Phase 1 A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors July 28, 2010 April 4, 2012
NCT01170052 Withdrawn Phase 1/Phase 2 Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) May 2010 April 2014
NCT00788580 Withdrawn Phase 1 S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
NCT01851408 Withdrawn Phase 2 Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma April 2006 February 2012
NCT01326468 Withdrawn N/A Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer January 2011
NCT01781442 Withdrawn A Post Marketing Surveillance As Required By Philippine Food And Drug Administration June 2013 June 2015